In this episode of "In the Interim," we consider the nuances of adaptive design clinical trials with distinguished guests Dr. Scott Berry and Dr. Kert Viele from Berry Consultants. The conversation centers around the vital question: when should these adaptive designs be implemented? Listeners will gain invaluable insights into the mechanics of adaptive trials, the Bayesian approach, and scenarios where these designs prove most effective. Whether you're involved in clinical research or simply intrigued by the evolution of clinical trials, this episode enriches your understanding with expert perspectives and practical examples.
Key Highlights:
- Dr. Scott Berry and Dr. Kert Viele discuss the core principles and benefits of adaptive design clinical trials.
- A distinction is drawn between adaptive and fixed trials, showcasing the flexibility and efficiency of adaptive methods.
- The speakers explore common adaptations, including sample size modifications and response adaptive randomization.
- Strategies to handle anticipated regret and buyer's remorse in trial design are thoroughly examined.
- The episode provides practical advice on identifying suitable scenarios for adaptive trials, emphasizing the importance of timely information.
Quotes:
- "The promise of an adaptive trial is creating prospective changes based on the accumulating data." – Dr. Scott Berry
- "If I knew enough to perfectly design my trial, I wouldn't need to run my trial because I already know what the answers are." – Dr. Kert Viele
- "Anticipated regret is one of the great answers to when you should adapt." – Dr. Scott Berry
- "You always get a net gain from looking at the data." – Kert Viele
